This report describes a patient with acute-type adult T cell leukemia/lymphoma (ATLL) successfully treated by autologous CD34
Human T lymphotrophic virus type I (HTLV-I) is endemic in Japan and associated with ATLL. ATLL is recognized as a distinct clinical entity and one of the common forms of leukemia in southwestern Japan, where roughly 700 new cases are diagnosed each year. 1 ATLL is an aggressive neoplasm characterized by uncontrolled T cell proliferation with one of several HTLV-I proviruses integrated within the cellular genome. Although the precise mechanism of ATLL oncogenesis is unknown, the regulatory gene tax, located at the pX region of the HTLV-I genome, is considered to be responsible for viral replication and the abnormal growth and immortalization of HTLV-I-infected T cells. 2 There is no standard therapy for ATLL. 3 Traditional antileukemic regimens may reduce tumor burden, but with limited benefit. Recently, an intensive combination chemotherapy regimen plus granulocyte colony-stimulating factor (G-CSF) was evaluated in ATLL patients, 4 but the duration 
Case summary
In July 1997, a female aged 49 years, originally from the island of Kyushu in southwestern Japan, presented with peripheral lymphadenopathy, a febrile episode, skin lesions, hypercalcemia without lytic bone lesions, and circulating lymphocytes with lobulated nuclei. Pathological examination of biopsy specimens of a cervical lymph node and skin revealed T cell malignancy, and a cell surface marker study identified a CD4 + /CD8 Ϫ and Tac antigen+ phenotype. The diagnosis of acute type of ATLL was confirmed by demonstrating positive serology and monoclonal integration of HTLV-I proviral DNA in malignant cells. The patient was given six courses of VEPAM chemotherapy (vincristine, cyclophosphamide, prednisone, adriamycin and methotrexate, as described in Ref. 6) , which led to a hematological remission. Since she did not have a suitable donor, either related or matched unrelated, peripheral blood progenitor cell (PBPC) harvest was performed with a Cobe Spectra Cell Separator (Cobe BCT, Lakewood, CO, USA), following high-dose etoposide and G-CSF mobilization. After this procedure, CD34 + cells were isolated by an immunomagnetic bead method (Isolex system; Nexell Therapeutics, Irvine, CA, USA). Ten months after presentation, autologous CD34
+ positive selected PBPC transplantation was performed. The patient was conditioned with 8 g/m 2 cytarabine and 120 mg/m 2 cyclophosphamide, followed by 1200 cGy total body irradiation. A total of 6.0 ϫ 10 7 CD34 + cells (1.2 ϫ 10 6 /kg) was transplanted. Treatment was tolerated without complications. Engraftment was uneventful with leukocytes above 1000/l on day 14 and platelets above 50 000/l on day 19. Although HTLV-I viremia persisted after transplantation, the patient was in sustained hematological and molecular remission. She was discharged in good general condition and was followed weekly in the outpatient clinic. However, 4 months post PBSCT she developed acute onset respiratory failure, deteriorated rapidly, and eventually died. At autopsy there was no evidence of recurrence of ATLL, but disseminated Toxoplasma gondii infection was detected.
Molecular investigation
Clonality of ATLL cells is usually verified by monoclonal integration of HTLV-I proviruses within the germ line by means of Southern blot analysis. However, this method is not sensitive enough to identify a small number of clonal cells. Recently, more sensitive methods, such as the inverse polymerase chain reaction (IPCR) have been established and can detect less than 1% ATLL cells among HTLV-Inon-infected cells. 5 We used this assay to assess the purging efficacy of the CD34 + positive selection method and to monitor minimal residual disease after transplantation. As shown in Figure 1a , a clonal band disappeared after the purging procedure which indicating high purging efficacy with apparent reduction of contaminated ATLL cells. Surprisingly, we could not amplify the pX region of HTLV-I after immunomagnetic CD34
+ cell selection (data not shown). This is probably due to the low levels of HTLV-I virus included during PBPC collection, which reflects the fact that HTLV-I is highly cell associated. DNA samples obtained from peripheral blood before and after transplantation were analyzed by IPCR. Figure 1b shows that although the monoclonal band was present before transplantation (lane 2), it could not be detected 1 and 2 months post transplant (lanes 3 and 4) . These data clearly demonstrate that the patient achieved a molecular remission after transplantation.
Discussion
Although long-term responses to combination chemotherapy, novel chemotherapeutic drugs and monoclonal antibodies against the interleukin-2 (IL-2) receptor have been reported in a few patients with the acute and lymphoma type of ATLL, median survival still ranges from 4 to 6 months. 7 Conventional chemotherapy led to marked improvement in our patient with acute-type ATLL but the likelihood of relapse warranted a transplant. Recently, Borg et al 8 has reported successful treatment of ATLL by allogeneic bone marrow transplantation which showed a sustained complete remission in ATLL 23 months after the transplantation. However, since our patient did not have a suitable donor for an allogeneic transplant, an autologous PBSCT with manipulation to eliminate tumor cells was undertaken. Anti-Tac antibody and IL-2-linked diphtheria toxin therapy 9, 10 targeting the ATLL cell population are currently being evaluated as experimental approaches but they are not easily performed in clinical settings. Therefore, a positive selection method using a CD34
+ cell enrichment procedure commonly employed in many centers was applied to eliminate ATLL cells in an attempt to reduce the possibility of relapse. Since cell populations expressing the surface antigen CD34 usually do not carry HTLV-I provirus, 11 our procedure could effectively eliminate the ATLL cells from the PBPC collections while preserving rapid engraftment capability. In fact, we demonstrated successful use of autologous CD34
+ -enriched PBPC for rapid hematopoietic reconstitution following myeloablative chemoirradiation therapy and also showed apparent depletion of the contaminating ATLL cells (Figure 1a) . Since IPCR could efficiently detect a monoclonality derived from increased HTLV-I-infected cells in HTLV-I carrier state, 5 disappearance of a monoclonal band from the peripheral blood sample (Figure 1b) suggested that the patient achieved a simple carrier state after transplantation. Although persistent HTLV-I viremia was confirmed by PCR amplification of the pX region of HTLV-I, possible infection of normal lymphocytes may not lead to a recurrence of ATLL, because the rate of malignant transformation is considered to be less than a 5% life-time risk. 12 Thus, autologous CD34 + PBSCT could have reduced the possibility of early relapse in our patient. Since the patient died of disseminated toxoplasmosis, long-term follow-up to evaluate the effect of persistent viremia on the patient was impossible. However, refinements in our therapic strategy might ultimately allow for prolonged disease-free survival or even cure in ATLL patients. Recent efforts have focused on modulating the production of various cytokines and using novel cytotoxic and antiviral chemotherapy therapies. Nucleoside analogues such as zidovudine have been reported to inhibit HTLV-I in vitro. 13 Although there is little evidence of their usefulness in vivo, these agents might be used as post-transplant adoptive therapy.
While the patient achieved a sustained molecular remission in ATLL after transplantation, immunosuppression as a consequence of T cell depletion and resultant Toxoplasma gondii reactivation ruined the promising outcome of transplantation. A prudent clinical attitude toward immunological fragility is needed for better outcome.
